KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Notes Payables (2017 - 2023)

Historic Notes Payables for Pacific Biosciences Of California (PACB) over the last 6 years, with Q4 2023 value amounting to $500000.0.

  • Pacific Biosciences Of California's Notes Payables fell 7826.09% to $500000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $500000.0, marking a year-over-year decrease of 7826.09%. This contributed to the annual value of $500000.0 for FY2023, which is 7826.09% down from last year.
  • According to the latest figures from Q4 2023, Pacific Biosciences Of California's Notes Payables is $500000.0, which was down 7826.09% from $2.3 million recorded in Q4 2022.
  • In the past 5 years, Pacific Biosciences Of California's Notes Payables registered a high of $15.9 million during Q4 2019, and its lowest value of $500000.0 during Q4 2023.
  • For the 4-year period, Pacific Biosciences Of California's Notes Payables averaged around $9.4 million, with its median value being $14.9 million (2019).
  • As far as peak fluctuations go, Pacific Biosciences Of California's Notes Payables skyrocketed by 4303.48% in 2022, and later crashed by 7826.09% in 2023.
  • Quarter analysis of 4 years shows Pacific Biosciences Of California's Notes Payables stood at $15.9 million in 2019, then plummeted by 89.87% to $1.6 million in 2021, then soared by 43.03% to $2.3 million in 2022, then plummeted by 78.26% to $500000.0 in 2023.
  • Its last three reported values are $500000.0 in Q4 2023, $2.3 million for Q4 2022, and $1.6 million during Q4 2021.